Recently, tumor markers CEA, CA19-9, CA72-4, and CA125 are widely used in gastric cancer patients, although reports have shown the value of tumor markers as prognostic factors, clinical studies evaluating the roles of tumor markers in monitoring of chemotherapeutic efficacy are limited [9], especially in neoadjuvant chemotherapy. The gene discussed is CEACAM5; the disease is neoplasm.